key: cord-1022167-6aodyl7c authors: Hai, R.; Collin, M.; Tsau, S.; Raygoza, D.; Morrison, J.; Carrillo, A. J.; Collier, L. A.; Bayubay, W.; Han, K.; Kaloshian, I.; Borkovich, K. A. title: Laboratory-Developed Test for SARS-CoV-2 Using Saliva Samples at the University of California, Riverside date: 2021-02-26 journal: nan DOI: 10.1101/2021.02.21.21251691 sha: 80b09ac1044bdd08ad914ae626808ff7665f8dcd doc_id: 1022167 cord_uid: 6aodyl7c Here we describe a relatively quick, simple, economical and accurate laboratory developed test (LDT) for detection of SARS-CoV-2 in heated and diluted saliva samples without RNA extraction. Our protocol is a variation of the University of Illinois Urbana-Champaign SHIELD LDT. Differences include chilling of the samples during dilution and using a reduced volume for the qRT-PCR reactions. The level of detection for our LDT is 3125 copies/ml, which compares favorably with other saliva-based tests. Initial validation studies with a limited number of patient samples have demonstrated excellent agreement between results using our LDT and those obtained from external laboratories. The cost of consumables for our test is under $8 and a throughput of 1000 tests/day can be achieved with 3-4 personnel. Several FDA-approved, commercially available diagnostic tests use reverse transcription combined with the polymerase chain reaction (RT-PCR). The University of California Riverside (UCR) Clinical Laboratory Improvement Amendments (CLIA) Extension Laboratory is using a modified version of the Laboratory Developed Test (LDT) established by the University of Illinois, Urbana-Champaign (UIUC) (1). This test detects the presence of three viral genes: N-gene, Sgene and ORF1ab, with spiked MS2 phage as a sample control. The qRT-PCR is performed using the "TaqPath COVID-19 Combo Kit" marketed by Thermo Fisher Scientific (EUA200010/A001) (2) as described in the UIUC LDT. This decision was made in order to 1) maximize the biosafety practice; 2) simplify the experimental procedure, while retaining reasonable sensitivity, and 3) ensure a ready supply of test reagents, plasticware and other consumables. Because we introduced several modifications to the UIUC protocol, including chilling samples during the dilution step and using a different volume for the qRT-PCR reactions, this modification is an LDT as described by CMS (3) and the FDA (4). Thus, we are required to establish analytical and clinical validity of our adaptation of the test through experiments determining our limit of detection and through bridging assays comparing our results to those of other authorized testing sites. We consider our test to have the following advantages: 1) We reduce cost and make the supply chain more sustainable by using a lower volume of Master Mix (5µl) for the qRT-PCR step. 2) Our test uses readily available consumables and is high throughput. We are utilizing 2-ml tubes for saliva collection that fit directly into our equipment. Multiple automated liquid handling robots are used for sample transfers. 3 3) The original saliva sample tube is not opened until after the heating step and inactivation of the virus, thus ensuring safety of the operators. 4 ) We chill samples after heating and during the dilution step, in order to better preserve the viral RNA. We Laboratory Director from UCR Environmental Health and Safety. All laboratory personnel were trained according to the approved SOPs and registered with CDPH. All personnel received HIPAA training. Using only barcoded samples with no protected health information on the tubes or on the laboratory computers ensured HIPAA compliance in the laboratory. As mentioned above, our assay is based on the University of Illinois Urbana-Champaign SHIELD LDT for detection of SARS-CoV-2 in saliva samples (1). Each individual being sampled is provided with a fact sheet that describes the test being performed, possible results and the limitations of the test. They are also given a consent form to sign. They then generate a barcode label using a QR code on their phone and their ID. The individual is then given the barcode label, a 2-ml collection tube and a transfer pipet. The individual withdraws pooled saliva (not sputum) from inside the bottom cheek using the sterile transfer pipet. A volume of at least 0.5ml is transferred to the 2-ml barcoded tube. The tube is securely capped and placed inside a secondary container. The transfer pipet containing excess saliva is discarded in a waste bag. Samples are then transported to the CLIA extension lab for testing. Accessioning: Personnel #1, in full PPE, moves the container with the specimen tubes to the biosafety cabinet (BSC). Personnel #1 cleans the surface of each tube with an antiviral medical wipe and holds it so that Personnel #2 (in full PPE) can scan the barcode into the "Specimen Intake Log" file accessible on the computer. Samples are rejected if they have illegible or missing labels, significantly less volume than 0.5ml or large amounts of food particles. Personnel #2 notes the failed samples and Personnel #1 discards the failed samples in the . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 26, 2021. ; https://doi.org/10.1101/2021.02.21.21251691 doi: medRxiv preprint qRT-PCR. Master Mix is prepared on ice or in a chilling rack using 0.5µl TaqPath RT-PCR COVID-19 Kit (Thermo Fisher Scientific, A47817) (2), 2µl TaqPath 1-step (Thermo Fischer Scientific, A28523), 1.5 µl nuclease-free water and 1µl of MS2 phage for each sample. A multichannel pipet is used to dispense 5µl of master mix to each well of a PCR plate on ice or a chilling rack. Plates are used immediately. The plate is brought to the OT-2 liquid handler in the BSC that contains the heated and diluted saliva sample plate. The Dilution/Aliquoting protocol is then resumed, transferring 5µl of each diluted sample to a position in the 96-well PCR plate (plate is kept on ice or in a chilling rack). Negative and positive controls are then added to wells A1 and A12, respectively. PCR plates are sealed and transferred immediately to the qRT-PCR step. After completion of the Dilution/Aliquoting program, the 96-well plates containing the leftover diluted samples are sealed and placed at -80°C for long-term storage. The 96-well RT-qPCR plate is then transferred to the Applied Biosystems Quant Studio 5 thermocycler. The RT-qPCR is run using the standard mode, consisting of a hold stage at 25°C for 2 min, 53°C for 10 min, and 95°C for 2 min, followed by 40 cycles of a PCR stage at 95°C for 3 sec then 60°C for 30 sec; with a 1.6°C/sec ramp up and ramp down rate. The EDS output file produced during each qRT-PCR run is analyzed using the QuantStudio Design and Analysis software (version 1.2). The EDS file is then analyzed using the Applied Biosystems COVID-19 Interpretative Software and a CSV-formatted report generated. The software determines the results and validity of all tests, using predetermined cut-offs (see Table 1 ). The EDS file produced during the qRT-PCR run is then opened and the amplification plots for wells are compared to the CSV report. The amplification plots for the wells containing negative and positive controls and those producing invalid, inconclusive or positive results are visually checked for abnormalities. If an abnormality is observed, the result is discussed with the . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 26, 2021. ; https://doi.org/10.1101/2021.02.21.21251691 doi: medRxiv preprint Laboratory Director to decide the next step. The CSV report file is then submitted to Student Health Services for reporting to patients and public health authorities. To minimize the overall cost of our assay, and to limit reagent use in the face of potential shortages, we reduced the quantity of reagents used for the RT-qPCR assay. After preliminary experiments showed that the test performed stably after such a reduction, we validated our workflow using 10µl total volume (5µl master mix and 5µl heated and diluted sample). We report the assay validation data conducted with the reduced volume protocol. Validating an LDT requires measuring specific FDA/CDC-defined metrics and meeting or exceeding benchmarks. In the case of our SARS-CoV-2 LDT, these metrics were: FDA policy recommends identifying the LOD of a molecular diagnostic by conducting a dilution series of SARS-CoV-2 RNA (or inactivated virus) in an artificial or real clinical matrix (4). This guidance recommends that "laboratories test a dilution series of three replicates per concentration, and then confirm the final concentration with 20 replicates." For the purposes of . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 26, 2021. an EUA, the FDA defines the limit of detection as "the lowest concentration at which 19/20 replicates are positive." In this section we describe the experimental data that establish the LOD of our LDT. To experimentally determine our limit of detection, two different operators performed serial dilutions of SARS-CoV-2 positive control RNA with 5 replicates each, using 25 x 10 3 , 12.5 x 10 3 , 6250, 3125 and 1562.5 copies/ml (Fig. 1) . Each sample was spiked with bacteriophage MS2 as a control. At each dilution, we determined the Ct (cycle threshold) of three SARS-CoV-2 genes Positive control SARS-CoV-2 RNA from the Thermo-Fisher kit was diluted serially using saliva from negative donors that had been heated and diluted using TBE-Tween using our protocol. Samples from dilutions containing the indicated concentration of viral RNAs were combined with master mix and subjected to qRT-PCR according to the Assay Description. Ct values for the three viral genes (N, S and ORF1ab) and the MS2 bacteriophage control were plotted. At our lowest concentration tested, 1562.5 copies/ml, we observed that the S gene was not amplified in two replicates and that ORF1ab was not amplified in one replicate. However, we detected amplification of all three SARS-CoV-2 genes at the four highest concentrations tested, 3125, 6250, 12.5 x 10 3 , and 25 x 10 3 copies/ml. As expected, the MS2 control was amplified in . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 26, 2021. ; https://doi.org/10.1101/2021.02.21.21251691 doi: medRxiv preprint all samples. Based on these results, the limit of detection of our assay is 3125 viral genome copies per milliliter. We tested the reproducibility of the two lower concentrations used for the LOD study (1562.5 and 3125 genomic copies/ml) by performing the assay using 20 total technical replicates at each concentration (Fig. 2) . Samples were spiked with bacteriophage MS2 as a control. Positive control SARS-CoV-2 RNA from the Thermo-Fisher kit was diluted to 1562.5 copies of each RNA/ml (TOP) or 3125 copies of each RNA/ml (BOTTOM) using saliva from negative donors that had been heated and diluted using our protocol. Samples were combined with master mix and subjected to qRT-PCR. Ct values for the three viral genes (N, S and ORF1ab) and the MS2 bacteriophage control were plotted. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 26, 2021. ; https://doi.org/10.1101/2021.02.21.21251691 doi: medRxiv preprint Three of the 1562.5 genomic copies/ml replicates failed to amplify one of the three viral genes. In contrast, we detected all three SARS-CoV-2 genes, as demonstrated by consistent, positive Ct values, in the 3125 genomic copies/ml samples. This is exceeding the required 19 out of 20 as defined by the FDA, and establishes 3125 viral genome copies per milliliter as our Our LOD of 3215 copies/ml compares favorably with other LDTs and EUAs for qRT-PCR detection of SARS-CoV-2 in saliva samples without RNA extraction. For example, the LOD for the UIUC SHIELD LDT is 1000 copies/ml (1), while the LOD for the Yale SalivaDirect EUA is 6000-12,000 copies/ml (5). To meet the clinical validity criterion, 100% of all non-spiked saliva samples must be negative. To control for nonspecific amplification, we ran presumed negative saliva samples using our protocol (Fig. 3) . . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 26, 2021. MS2 yielded the expected Ct values for the 30 replicates, with no detectable amplification of any SARS-CoV-2 genes in any of the MS2-spiked saliva samples (Fig. 3) . The SARS-CoV-2 positive control from Thermo Fisher exhibited the expected amplification of all three SARS-CoV-2 genes, and the absence of MS2 phage (data not shown). This result demonstrates that nonspecific amplification of SARS-CoV-2 genes was not observed in 30/30 samples, supporting a low false-positive rate for our LDT. We are using the Thermo-Fisher TaqPath COVID-19 Combo Kit for qRT-PCR, as done previously for SHIELD at UIUC (1). Therefore, we are using the parameters established for interpretation of results using nasal pharyngeal swabs/RNA extraction by Thermo-Fisher for their EUA (Table 1) . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 26, 2021. ; https://doi.org/10.1101/2021.02.21.21251691 doi: medRxiv preprint We further validated our assay and workflow by submitting nasal swab or saliva samples from patients with positive and negative saliva test results for analysis at a different testing facility ( Table 2 . Comparison of results from the UCR CLIA Extension Laboratory with those from external laboratories. Samples from 18 patients (ID# 1-18) were tested by the UCR CLIA Extension laboratory (Saliva/PCR) and an external testing laboratory (Nasal Swab/PCR or Saliva/Antigen). *The sample analyzed by the UCR laboratory was collected a week after the nasal swab sample was obtained for analysis by the outside laboratory. The results for 17/18 clinical samples exactly matched those obtained for saliva samples using our LDT (94.4% agreement). Ct values for the known positive specimens spanned a large range (data not shown), supporting the dynamic range of our assay for clinical validation. Sample ID#7 was inconclusive according to results from the UCR testing laboratory and positive using a nasal swab sample at an external laboratory-it should be noted that this patient was recovering from COVID symptoms and a week had elapsed after the nasal swab sample was taken before the saliva sample was obtained and tested. Thus, it is possible that the viral load had decreased during the intervening week, leading to an inconclusive saliva test result from our LDT. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted February 26, 2021. ; https://doi.org/10.1101/2021.02.21.21251691 doi: medRxiv preprint Saliva-Based Molecular Testing for SARS-CoV-2 that Bypasses RNA Extraction Thermo Fisher Scientific TaqPath COVID-19 Combo Kit. Instructions for Use Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised) Accelerated Emergency Use Authorization (EUA) Summary SARS-CoV-2 RT-PCR Assay